CCN3 has anti-tumor effects in breast cancer (Dobson et al., 2014), colorectal tumors (Li et al., 2017), kidney cancer (Liu et al., 2012), glioma (Gupta et al., 2001), and leukemia (McCallum et al., 2012). This evidence concerns the gene CCN3 and central nervous system cancer.